• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Antitumor activity of the combination of arsenic compound and tetrandrine against human breast cancer

Research Project

Project/Area Number 17K08465
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Medical pharmacy
Research InstitutionJosai University (2019)
Tokyo University of Pharmacy and Life Science (2017-2018)

Principal Investigator

Yuan Bo  城西大学, 薬学部, 准教授 (10328552)

Project Period (FY) 2017-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords乳がん / ヒ素化合物 / テトランドリン / オートファージ / 細胞周期 / MAPK / 細胞死 / 腫瘍免疫 / アポトーシス / ネクローシス / ヒト乳がん / 薬学 / 臨床 / 癌
Outline of Final Research Achievements

The effects of arsenic compounds (As) and tetrandrine (Tetra), alone or in combination, against human breast cancer tissue were conducted in order to develop new therapeutic strategies to combat breast cancer. Treatment with As combined with Tetra appeared to reduce the viability of cancer tissues, along with the downregulation of the secretion of IL-6 and IL-10, and upregulation of the secretion of IL-17A and TNF, respectively. Moreover, exposure of the combined treatment to different types of breast cancer cell lines (MDA-MB-231, MCF-7 and T-47D) resulted in proliferation inhibition, which appeared to be associated with cell death, cell cycle arrest and differentiation induction. These findings thus suggest that the combination can probably serve as promising candidates for the development of novel therapeutic approaches for different types of breast cancer. Further investigation into the effects of the combined regimen on patient-derived breast cancer xenografts should be warranted.

Academic Significance and Societal Importance of the Research Achievements

早期発見・診断および分子標的治療が進んだ今でも、乳がんで死亡する女性の割合が年々増加する傾向にあると報告され、加えて臨床上の薬物耐性、副作用が依然として大きな問題となっており、効果的な新規治療法の開発が望まれている。本研究は、臨床上に白血病に対する優れた治療効果を有するヒ素化合物に着眼し、抗がん剤の治療効果を高めるとともにその副作用を軽減することが期待できるテトランドリンとの併用に注目した。外科的に切除されたヒト乳がん組織、および遺伝学的な違いのある三種類の乳がん細胞に対する両薬物の単独および併用効果を検討することにより、改めて両薬物の併用は乳がん治療に対する有望な治療法であることを示唆した。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (11 results)

All 2020 2019 2018 2017 Other

All Journal Article (5 results) (of which Int'l Joint Research: 3 results,  Peer Reviewed: 5 results,  Open Access: 3 results) Presentation (4 results) (of which Int'l Joint Research: 1 results) Remarks (2 results)

  • [Journal Article] ヒ素化合物の抗腫瘍活性およびその新規臨床応用の可能性2020

    • Author(s)
      袁 博, 岡崎 真理, 平野 俊彦
    • Journal Title

      ファルマシア

      Volume: 56(5) Pages: 421-425

    • NAID

      130007841812

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents.2019

    • Author(s)
      Hidetomo Kikuchi, Bo Yuan, Xiaomei Hu, Mari Okazaki
    • Journal Title

      American Journal of Cancer Research

      Volume: 9(8) Pages: 1517-1535

    • NAID

      120006763887

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] ヒ素化合物とテトランドリン併用の乳癌治療応用への可能性2019

    • Author(s)
      袁 博, 清海 杏奈, 平野 俊彦
    • Journal Title

      メディカル・サイエンス・ダイジェスト

      Volume: 45(8) Pages: 59-61

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Differentiation induction of human breast cancer cells by arsenite in combination with tetrandrine.2019

    • Author(s)
      Bowen Yu, Bo Yuan, Anna Kiyomi, Hidetomo Kikuchi, Hideki Hayashi, Xiaomei Hu, Mari Okazaki, Munetoshi Sugiura, Toshihiko Hirano, Xiaohua Pei, Norio Takagi
    • Journal Title

      American Journal of Translational Research

      Volume: 11(12) Pages: 7310-7323

    • NAID

      120006808548

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Antitumor activity of arsenite in combination with tetrandrine against human breast cancer cell line MDA-MB-231 in vitro and in vivo2018

    • Author(s)
      Yuan Bo、Yao Mingjiang、Wang Xiao、Sato Ai、Okazaki Ayane、Komuro Hana、Hayashi Hideki、Toyoda Hiroo、Pei Xiaohua、Hu Xiaomei、Hirano Toshihiko、Takagi Norio
    • Journal Title

      Cancer Cell International

      Volume: 18 Issue: 1 Pages: 113-113

    • DOI

      10.1186/s12935-018-0613-0

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] ヒト乳がん細胞に対するAsIIIとテトランドリンの併用による分化誘導作用2019

    • Author(s)
      袁 博、清海 杏奈、菊地 秀与、林 秀樹、杉浦  宗敏、平野 俊彦、高木 教夫、岡﨑 真理
    • Organizer
      日本薬学会 第140年会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Contributions of apoptosis induction and JNK activation to enhanced cytotoxicity of arsenite and tetrandrine in human breast cancer cell line MDA-MB-2312018

    • Author(s)
      BoWen Yu, Bo Yuan, Anna Kiyomi, Sachiko Tanaka, Hideki Hayashi, Munetoshi Sugiura, Toshihiko Hirano, XiaoHua Pei, Norio Takagi
    • Organizer
      第91回日本生化学会
    • Related Report
      2018 Research-status Report
  • [Presentation] ヒト乳がん細胞MCF-7に対するAsIIIとテトランドリンの併用による相乗的な殺細胞作用2018

    • Author(s)
      袁 博,王 瀟,姚 明江,林 秀樹,平野 俊彦,高木 教夫
    • Organizer
      第138回日本薬学会
    • Related Report
      2017 Research-status Report
  • [Presentation] Enhanced cytotoxic effects of the combination of arsenite with tetrandrine against breast cancer cell line MCF-72017

    • Author(s)
      Bo Yuan, Mingjiang Yao, Hideki Hayashi, Toshihiko Hirano, Norio Takagi
    • Organizer
      14th Asia Pacific Oncologists Annual Meeting
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research
  • [Remarks] 城西大学機関リポジトリ JURA

    • URL

      http://libir.josai.ac.jp/il/meta_pub/G0000284repository_JOS-21566976_9_1517

    • Related Report
      2019 Annual Research Report
  • [Remarks] 城西大学機関リポジトリ JURA

    • URL

      https://libir.josai.ac.jp/il/meta_pub/G0000284repository_JOS-19438141-11-7310

    • Related Report
      2019 Annual Research Report

URL: 

Published: 2017-04-28   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi